JAMM Technologies, LLC announced last week that it has purchased a portfolio of assets from Veriteq Corporation, including its implantable RFID solutions, UDI business and intellectual property. The company also disclosed that it has entered into a long term supply agreement with Establishment Labs to provide implantable micro-transponder technology for their current and next generation family of silicone breast implants.
JAMM Technologies has begun implementing its vision to become an identification and reference platform for implantable medical devices. “All long term implantable devices should have RFID technology to provide key information on the safety and functionality of these devices,” said Randy Geissler, Chief Technology Officer of JAMM Technologies. “The ability for doctors to identify and communicate with implantable medical devices will allow for the development of smart devices that increase both safety and health.”
Juan Jose Chacón Quirós, CEO of Establishment Labs, added, “Implantable RFID technology is one of the most exciting technologies in medical devices. Our agreement with JAMM secures the supply of Q Inside Safety Technology™ and the future development of diagnostic capabilities in biosensors for the next generation of Motiva breast implants.”
There have been over 40,000 implantations of Motiva Implants® with Q Inside Safety Technology™ in the European Union and Japan. Q Inside Safety Technology™ is an FDA cleared and CE approved RFID solution that allows plastic surgeons to connect patients through the MotivaImagine™ App to an electronic passport that contains all the relevant information about the breast implant for increased safety and peace of mind.
We are very pleased that this agreement means Motiva implants will continue to offer Q inside safety technology, providing the highest level of safety for patients.